Glaucoma

The effect of travoprost on daytime intraocular pressure in normal tension glaucoma: a randomised co
BACKGROUND/AIMS: To determine the medium-term effect of travoprost on the daytime intraocular pressure (IOP) of patients with normal tension glaucoma (NTG).
Colney Lane
Norwich, UK
UK
Reversal of optic disc cupping in glaucoma
AIM: To study whether reversal of optic disc cupping after intraocular pressure (IOP) reduction is related to risk of glaucoma progression.
Haartmaninkatu 4 C, PO Box 220, 00029 Hus
Finland,
Finland
Brimonidine-purite 0.1% versus brimonidine-purite 0.15% twice daily in glaucoma or ocular hypertensi
OBJECTIVE: To compare the safety and intraocular pressure (IOP)-lowering effects of brimonidine-purite 0.1% with the marketed formulation of brimonidine-purite 0.15% (Alphagan P 0.15%) when used twice daily (BID) by patients with glaucoma or ocular hypertension previously treated with brimonidine-purite 0.15% for at least 6 weeks.

Indianapolis, IN 46202
USA
Longitudinal rates of postoperative adverse outcomes after glaucoma surgery among medicare beneficia
PURPOSE: To determine longitudinal rates of postoperative adverse outcomes after incisional glaucoma surgery in a nationally representative longitudinal sample.

Ann Arbor, MI
USA
Comparative study of the stability of bimatoprost 0.03% and latanoprost 0.005%: a patient-use study
BACKGROUND: The stability of ophthalmic preparations in multidose containers is influenced by the preservative as well as the stability of the active ingredient.

São Paulo, Brazil
Brazil
Amniotic membrane transplantation in trabeculectomy with mitomycin C for refractory glaucoma
PURPOSE: To compare outcomes of trabeculectomy combined with mitomycin C (MMC) and amniotic membrane transplantation (AMT) with those of trabeculectomy with MMC alone in refractory glaucoma.

Jeddah, Saudi Arabia
Saudi Arabia
The effect of selective laser trabeculoplasty on intraocular pressure in patients with intravitreal
PURPOSE: To assess effectiveness of selective laser trabeculoplasty (SLT) in lowering intraocular pressure (IOP) in patients with steroid-induced elevated IOP.

New York, NY
USA
Long-term relationship between intraocular pressure and visual field loss in primary open-angle glau
PURPOSE: To investigate the dependence upon intraocular pressure (IOP) of the progression of visual field defects in eyes with primary open-angle glaucoma (POAG), in which the mean IOP was maintained at < or =21 mm Hg.


Japan
Aqueous shunts in glaucoma: a report by the American Academy of Ophthalmology
OBJECTIVE: To provide an evidence-based summary of commercially available aqueous shunts currently used in substantial numbers (Ahmed [New World Medical, Inc., Rancho Cucamonga, CA], Baerveldt [Advanced Medical Optics, Inc., Santa Ana, CA], Krupin [Eagle Vision, Inc, Memphis, TN], Molteno [Molteno Ophthalmic Ltd., Dunedin, New Zealand]) to control intraocular pressure (IOP) in various glaucomas.


USA
Molecular and cell-based approaches for neuroprotection in glaucoma
A hallmark of glaucomatous optic nerve damage is retinal ganglion cell (RGC) death. RGCs, like other central nervous system neurons, have a limited capacity to survive or regenerate an axon after injury.

Montreal, Quebec
Canada